Oxytocin is under clinical development by OT4B and currently in Phase III for Prader-Willi Syndrome (PWS). According to GlobalData, Phase III drugs for Prader-Willi Syndrome (PWS) have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Oxytocin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oxytocin is under development for the treatment of Prader-Willi syndrome in pediatrics, children and adults. It is administered through nasal route. The drug candidate acts by targeting oxytocin receptor.
OT4B is a biomedical company developing novel therapeutic solutions for the treatment of Prader-Willi syndrome. Its pipeline comprises Phase I and Phase II clinical studies, which focus on evaluating the administration of intranasal oxytocin in infants with Prader-Willi syndrome. The company is also advancing pipeline programs for evaluating the effect of oxytocin in Prader-Willi syndrome in phase II and III clinical studies for children and adults. OT4B advances its clinical programs in collaboration with Toulouse University Hospital. The company is funded by the La French Tech, bpifrance, and Galpaco. OT4B is headquartered in Toulouse, Midi Pyrenees, France.
For a complete picture of Oxytocin’s drug-specific PTSR and LoA scores, buy the report here.